BR112015006727B1 - Uso de uma composição farmacêutica - Google Patents

Uso de uma composição farmacêutica Download PDF

Info

Publication number
BR112015006727B1
BR112015006727B1 BR112015006727-1A BR112015006727A BR112015006727B1 BR 112015006727 B1 BR112015006727 B1 BR 112015006727B1 BR 112015006727 A BR112015006727 A BR 112015006727A BR 112015006727 B1 BR112015006727 B1 BR 112015006727B1
Authority
BR
Brazil
Prior art keywords
day
acid
therapeutic compound
disclosed
aspects
Prior art date
Application number
BR112015006727-1A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015006727A2 (pt
BR112015006727A8 (pt
Inventor
Suzanne Jane Dilly
Gregory Alan Stoloff
Paul Christopher Taylor
Original Assignee
Tangent Reprofiling Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tangent Reprofiling Limited filed Critical Tangent Reprofiling Limited
Publication of BR112015006727A2 publication Critical patent/BR112015006727A2/pt
Publication of BR112015006727A8 publication Critical patent/BR112015006727A8/pt
Publication of BR112015006727B1 publication Critical patent/BR112015006727B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BR112015006727-1A 2012-09-26 2013-09-26 Uso de uma composição farmacêutica BR112015006727B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261705790P 2012-09-26 2012-09-26
US61/705790 2012-09-26
US201361871662P 2013-08-29 2013-08-29
US61/871662 2013-08-29
PCT/EP2013/070106 WO2014049071A1 (en) 2012-09-26 2013-09-26 Modulators of androgen synthesis

Publications (3)

Publication Number Publication Date
BR112015006727A2 BR112015006727A2 (pt) 2017-07-04
BR112015006727A8 BR112015006727A8 (pt) 2019-08-27
BR112015006727B1 true BR112015006727B1 (pt) 2022-08-16

Family

ID=49293617

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015006727-1A BR112015006727B1 (pt) 2012-09-26 2013-09-26 Uso de uma composição farmacêutica

Country Status (14)

Country Link
US (4) US9072743B2 (cg-RX-API-DMAC7.html)
EP (1) EP2900270B1 (cg-RX-API-DMAC7.html)
JP (2) JP6434410B2 (cg-RX-API-DMAC7.html)
CN (1) CN104797271B (cg-RX-API-DMAC7.html)
AU (2) AU2013322612B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015006727B1 (cg-RX-API-DMAC7.html)
CA (1) CA2886132C (cg-RX-API-DMAC7.html)
ES (1) ES2734554T3 (cg-RX-API-DMAC7.html)
HK (1) HK1211868A1 (cg-RX-API-DMAC7.html)
IL (2) IL237892B (cg-RX-API-DMAC7.html)
MX (1) MX367782B (cg-RX-API-DMAC7.html)
NZ (1) NZ706067A (cg-RX-API-DMAC7.html)
PL (1) PL2900270T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014049071A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2900270T3 (pl) 2012-09-26 2019-09-30 Tangent Reprofiling Limited Połączenie benzo(izo)oksazolopiperydyn ze sprzężonym kwasem linolowym
US9375433B2 (en) 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis
AU2015257594A1 (en) * 2014-05-09 2016-11-24 Tangent Reprofiling Limited Modulators of androgen synthesis
CA3049980A1 (en) 2017-01-23 2018-07-26 Regeneron Pharmaceuticals, Inc. Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
CA3059348A1 (en) 2017-04-11 2018-10-18 Regeneron Pharmaceuticals, Inc. Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (hsd17b) family
AU2018348195B2 (en) 2017-10-11 2025-05-15 Regeneron Pharmaceuticals, Inc. Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
MY207352A (en) 2018-03-21 2025-02-21 Regeneron Pharma 17-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4756911A (en) 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
JPH05502217A (ja) * 1989-08-21 1993-04-22 ベス イスラエル ホスピタル アソシエーション セロトニン拮抗薬の局所用調製物を使用した、皮膚、眼、および粘膜の過敏症、炎症、および過増殖状態の治療のための方法および組成物
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6319950B1 (en) 1997-02-18 2001-11-20 Michael C. Seidel Suppression of carcinoma using high purity conjugated linoleic acid (CLA)
JPH1192343A (ja) * 1997-09-22 1999-04-06 Shiseido Co Ltd 毛髪成長期延長剤
JPH11209279A (ja) * 1998-01-05 1999-08-03 Natural Ltd As 体重減少および肥満処置の方法
IL139975A0 (en) 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US6977271B1 (en) * 2001-08-30 2005-12-20 Health Research, Inc. Method for inhibition of angiogenesis and vasculogenesis
ES2186576B1 (es) * 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
EP1480629A1 (en) * 2002-02-08 2004-12-01 Abbott Laboratories Combination therapy for treatment of schizophrenia
WO2004103262A2 (en) * 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for modulation of suppressive activity of cd4+cd25+ regulatory t cells
WO2005066196A1 (en) 2003-12-30 2005-07-21 Ranbaxy Laboratories Limited Amorphous form of finasteride and processes for its preparation
EP1706095B1 (en) 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
EP1890700A2 (en) * 2005-05-31 2008-02-27 Orexigen Therapeutics, Inc. Methods and compositions for managing psychotic disorders
WO2008034129A2 (en) * 2006-09-15 2008-03-20 Cornell Research Foundation Inc. Treatment of cancer or obesity with conjugated linoleic acids
US8420624B2 (en) * 2007-12-04 2013-04-16 Yung Shin Pharm. Ind. Co., Ltd. Methods for treating or preventing symptoms of hormonal variations
AR070313A1 (es) 2008-01-03 2010-03-31 Gador Sa Un procedimiento para preparar una forma solida y cristalina de dutasteride, una forma polimorfica del compuesto (forma iii) y una composicion farmaceutica que incluye dicha forma
DK2280928T3 (en) * 2008-05-01 2018-11-05 Complexa Inc Vinyl-substituted fatty acids
CN101366705B (zh) * 2008-09-28 2010-09-08 浙江大学 利培酮透皮吸收贴片
US8420077B2 (en) 2009-04-20 2013-04-16 Allergan, Inc. Silk fibroin hydrogels and uses thereof
WO2012026663A1 (ko) * 2010-08-25 2012-03-01 이화여자대학교 산학협력단 운데실렌산, 공액리놀레산 및/또는 공액리놀레산 이성질체를 포함하는 항암보조제
EP2907504B1 (en) * 2011-02-08 2017-06-28 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
WO2014027973A1 (en) * 2012-08-14 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Paliperidone oral solution
PL2900270T3 (pl) 2012-09-26 2019-09-30 Tangent Reprofiling Limited Połączenie benzo(izo)oksazolopiperydyn ze sprzężonym kwasem linolowym
US9375433B2 (en) 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis
AU2015257594A1 (en) 2014-05-09 2016-11-24 Tangent Reprofiling Limited Modulators of androgen synthesis

Also Published As

Publication number Publication date
BR112015006727A2 (pt) 2017-07-04
IL237892A0 (en) 2015-05-31
AU2017221819A1 (en) 2017-09-21
CA2886132C (en) 2023-03-21
US20180064713A1 (en) 2018-03-08
AU2013322612A2 (en) 2015-04-09
CA2886132A1 (en) 2014-04-03
NZ706067A (en) 2016-07-29
US9585887B2 (en) 2017-03-07
US20150258095A1 (en) 2015-09-17
JP2019052159A (ja) 2019-04-04
AU2013322612B2 (en) 2017-06-01
BR112015006727A8 (pt) 2019-08-27
WO2014049071A1 (en) 2014-04-03
IL266446A (en) 2019-06-30
JP6734346B2 (ja) 2020-08-05
US9808462B2 (en) 2017-11-07
JP2015532920A (ja) 2015-11-16
AU2013322612A1 (en) 2015-04-09
CN104797271A (zh) 2015-07-22
EP2900270B1 (en) 2019-03-06
AU2017221819B2 (en) 2019-05-02
EP2900270A1 (en) 2015-08-05
JP6434410B2 (ja) 2018-12-05
MX367782B (es) 2019-09-04
ES2734554T3 (es) 2019-12-10
PL2900270T3 (pl) 2019-09-30
US9072743B2 (en) 2015-07-07
US20170189407A1 (en) 2017-07-06
US20140088120A1 (en) 2014-03-27
IL237892B (en) 2019-05-30
CN104797271B (zh) 2020-03-06
HK1211868A1 (en) 2016-06-03
MX2015003899A (es) 2015-11-25

Similar Documents

Publication Publication Date Title
AU2017221819B2 (en) Modulators of androgen synthesis
US10111877B2 (en) Modulators of androgen synthesis
EP3139923B1 (en) Composition for treating pancreatic adenocarcinoma
MX2007013854A (es) Composiciones y metodos para el tratamiento de neoplasmas.
JP2017514816A5 (cg-RX-API-DMAC7.html)
HK1123970A (en) Compositions for the treatment of neoplasms

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/09/2013, OBSERVADAS AS CONDICOES LEGAIS